Letter

Letter to insurers on rising price of insulin


12.06.19

Excerpt: “Unfortunately, even though the average net price that manufacturers are receiving for many insulin products is decreasing and PBMs are working with health plans to help reduce the cost of insulin for health plans, many Americans are facing increased out-of-pocket costs for their insulin at the pharmacy counter,” the leaders wrote in their letters. “We are therefore examining the role of insurers in the prescription drug supply chain, including questions about how insurers make decisions about plan design, the use of rebates in the insulin market, and the level of transparency between insurers and their supply chain partners”

Click here to read the letter to Anthem

Click here to read the letter to Blue Cross Blue Shield

Click here to read the letter to Cigna Corporation

Click here to read the letter to CVS Health

Click here to read the letter to Kaiser Permanente

Click here to read the letter to UnitedHealth Group

Letter